Shares in Wave Life Sciences Ltd. have hit the rocks after the company terminated development of suvodirsen following a dismal fail in a Duchenne muscular dystrophy trial.
The decision to discontinue suvodirsen came after an interim analysis of a Phase I open-label extension study in DMD patients...